missing translation for 'onlineSavingsMsg'
Learn More

R&D Systems™ Cyclic Pifithrin-α hydrobromide

Codice prodotto. 18085402
Cambia vista
Click to view available options
Quantità:
10 mg
Dimensione della confezione:
10mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Codice prodotto. Quantità Dimensione della confezione
18085402 10 mg 10mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Les retours ne sont pas autorisés pour ce produit. Consulta la politica di reso
Codice prodotto. 18085402 Fornitore R&D Systems™ N. del fornitore 3843/10
  • ONLINE EXCLUSIVE PRICE
    295.23 CHF
    258.30 CHF / 10 Milligramm
    Sparen 36.93 CHF
    12% Rabatt
 Articolo soggetto a restrizioni
Verfügbar ab: 26-11-2026
Aggiungi al carrello
Aggiungi al carrello

missing translation for 'validMainframeMsg'

Les retours ne sont pas autorisés pour ce produit. Consulta la politica di reso

A Tocris product, part of R&D Systems. p53 inhibitor

Cyclic Pifithrin-α hydrobromide is a cyclic analog of pifithrin-α (Cat. No. 1267), a small molecule inhibitor of p53. Prevents dexamethasone -induced cell death in murine thymocytes (EC50 = 2.01 μM). Sensitizes p53-deficient tumors to radiotherapy and chemotherapy; increases apoptosis in target cells when used in combination with antimicrotubule agents.
TRUSTED_SUSTAINABILITY

Chemical Identifiers

CAS 511296-88-1
Formula molecolare C16H17BrN2S

Specifications

Materiale o nome chimico Cyclic Pifithrin-α hydrobromide
Quantità 10 mg
Linea di prodotti Tocris
Peso formulazione 349.29
Purezza >98%
Peso molecolare 349.29
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.